[Anticoagulation. Modern concepts]

Related Experiment Video

Updated: May 22, 2026

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

M Perrey1, R Erbel

  • 1Klinik für Kardiologie/Westdeutsches Herzzentrum, Universitätsklinikum Essen, Hufelandstr. 52, 45147, Essen, Deutschland. mareike.perrey@uk-essen.de

Herz
|May 18, 2012
PubMed

Insights

Vitamin K antagonists are standard for atrial fibrillation (AF) stroke prevention but have drawbacks. New oral anticoagulants like rivaroxaban and dabigatran offer improved efficacy and safety, representing a promising alternative.

Area of Science:

  • Cardiology
  • Pharmacology
  • Neurology

Context:

  • Atrial fibrillation (AF) patients traditionally use vitamin K antagonists (VKAs) for stroke risk reduction.
  • VKAs require regular International Normalized Ratio (INR) monitoring, presenting challenges in compliance and achieving therapeutic ranges.
  • Despite efficacy, VKAs have limitations including a narrow therapeutic window and bleeding risks.

Purpose:

  • To review the efficacy and safety of novel oral anticoagulants (NOACs) compared to VKAs in AF patients.
  • To highlight the advantages of NOACs in stroke prevention and bleeding profiles.
  • To discuss the potential benefits of incorporating NOACs into clinical practice for AF management.

Summary:

  • Novel oral anticoagulants, including direct factor Xa inhibitors (e.g., rivaroxaban) and direct thrombin inhibitors (e.g., dabigatran), demonstrate comparable or superior efficacy to VKAs in preventing stroke in AF.
  • These newer agents show a significantly lower incidence of intracranial bleeding compared to warfarin.
  • NOACs offer improved convenience and a more favorable bleeding profile, simplifying anticoagulation management in AF.

Impact:

  • The introduction of NOACs provides a valuable alternative to VKAs, potentially improving patient adherence and outcomes in AF.
  • Enhanced stroke prevention with reduced bleeding complications can lead to better quality of life for AF patients.
  • These findings support the consideration of NOACs as a preferred option for anticoagulation in select AF populations.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...